Zacks Research Issues Pessimistic Forecast for BHC Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Research analysts at Zacks Research lowered their Q1 2025 earnings per share (EPS) estimates for shares of Bausch Health Companies in a note issued to investors on Tuesday, March 11th. Zacks Research analyst R. Department now expects that the company will earn $0.80 per share for the quarter, down from their previous forecast of $0.87. The consensus estimate for Bausch Health Companies’ current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2025 earnings at $1.27 EPS, FY2025 earnings at $4.26 EPS, Q2 2026 earnings at $1.10 EPS and Q3 2026 earnings at $1.28 EPS.

Several other equities analysts have also recently commented on the company. Royal Bank of Canada cut their price target on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a report on Thursday, January 30th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $8.00 price target (down previously from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, Bausch Health Companies has a consensus rating of “Hold” and a consensus target price of $7.42.

Bausch Health Companies Stock Up 3.7 %

Shares of NYSE:BHC opened at $7.15 on Friday. The business has a 50 day moving average price of $7.22 and a 200 day moving average price of $7.63. Bausch Health Companies has a twelve month low of $3.96 and a twelve month high of $11.46. The company has a market cap of $2.63 billion, a price-to-earnings ratio of -59.54, a PEG ratio of 0.37 and a beta of 0.59.

Bausch Health Companies (NYSE:BHC) last announced its earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The business had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.51 billion.

Hedge Funds Weigh In On Bausch Health Companies

A number of hedge funds have recently modified their holdings of the stock. CIBC Asset Management Inc raised its holdings in shares of Bausch Health Companies by 0.3% in the 3rd quarter. CIBC Asset Management Inc now owns 374,729 shares of the company’s stock worth $3,060,000 after buying an additional 1,082 shares in the last quarter. Tobam raised its holdings in shares of Bausch Health Companies by 10.4% in the 4th quarter. Tobam now owns 15,034 shares of the company’s stock worth $121,000 after buying an additional 1,422 shares in the last quarter. Toronto Dominion Bank raised its holdings in shares of Bausch Health Companies by 1.0% in the 4th quarter. Toronto Dominion Bank now owns 167,212 shares of the company’s stock worth $1,350,000 after buying an additional 1,712 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Bausch Health Companies by 7.9% in the 4th quarter. Wells Fargo & Company MN now owns 25,907 shares of the company’s stock worth $209,000 after buying an additional 1,896 shares in the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of Bausch Health Companies by 10.6% in the 4th quarter. American Century Companies Inc. now owns 27,236 shares of the company’s stock worth $220,000 after buying an additional 2,600 shares in the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.